Physicians consider more than what a drug does when making prescribing decisions. They also look at who is behind the therapy ...

Avalere Health has hired Corrina Safeio as its new president of global marketing and executive vice president of corporate ...

AbbVie’s migraine drug Ubrelvy (ubrogepant) is slated to be the top-selling drug in the migraine space in 2033 across the ...

With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...

Three months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO ...

When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

Gilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. But it looks ...

BMS ran its first C2C4C event in 2014, when an employee worked with colleagues to put together a team of 53 oncology staffers ...

After opting out of Teva’s $4.25 billion national opioid settlement last year, the city of Baltimore has secured its own payout through a settlement deal worth $80 million. | The city scored its own ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...

The Rybrevant-Lazcluze combo lowered the risk of death by 23% compared with Tagrisso in an updated analysis of the phase 3 ...

Why is PDA’s Universe of Pre-Filled Syringes and Injection Devices Conference the must-attend event of the year? Get an ...